Floatz logo

Amivantamab-Vmjw

Glioblastoma Multiform (Grade IV Astrocytoma)

Institute of Cancer Research, United Kingdommonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

353 Active assets in the Glioblastoma Multiform (Grade IV Astrocytoma) cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

Amivantamab-Vmjw is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
colorectal neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →